Clinical Trials Logo

Clinical Trial Summary

This Phase 2 study is conducted to assess the efficacy and safety of DS-1001b in patients with chemotherapy- and radiotherapy-naive IDH1 mutated WHO grade II glioma.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04458272
Study type Interventional
Source Daiichi Sankyo, Inc.
Contact
Status Active, not recruiting
Phase Phase 2
Start date July 8, 2020
Completion date June 30, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT04479696 - Customized Neuro-Imaging Referenced Symptom Video for the Reduction of Patient and Caregiver Anxiety Around Radiation Treatment for Brain Tumors N/A
Recruiting NCT03251027 - Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma N/A
Recruiting NCT04623931 - Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas Phase 2
Recruiting NCT04540107 - Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma Phase 1
Recruiting NCT03749187 - BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas Phase 1